Genefitletics launches Vascomath to fight cardiovascular diseases

Team L&M

Genefitletics has launched VASCOMATH, a machine learning driven human biology model that measures & quantifies molecular signatures underlying gut & oral microbiome functions to predict onset & progression of CVDs (cardiovascular diseases). The company asserts that VASCOMATH is the industry’s first prediction model that blends biochemistry & mathematics to elucidate biomarkers for CVD, years before disease manifests.

VASCOMATH mathematically integrates with Genefitletics’s Molecular Biology Platform, home to its suite of other prediction & early detection models for metabolic, oral diseases & cancer, to construct & deliver molecular data driven nutritional therapeutics interventions that eliminates early molecular signatures before CVD develops.

Sushant Kumar, Founder & CEO-Genefitletics, underscores the importance of oral & gut microbiome in addressing chronic diseases including cardiovascular diseases. With 1/3rd of deaths in India attributed to cardiovascular diseases, he accentuates that there is urgent need to measure the asymptomatic biochemical signatures that manifest decades before blood pressure elevates & cholesterol becomes abnormal.

Kumar also stresses on the role of oral health & regular dental screening in preventing the onset of cardiovascular diseases as the metabolic byproducts of oral microbiome can lead to plaque deposition in arteries & increase risk of cardiovascular diseases.

Genefitletics offers PROTEBA, a system biology platform, that collects, processes & analyses molecular & phenotype metadata data & overlays mathematical models to measure changes in biochemistry before disease manifests/at earliest stages & provide disease modifiable therapeutics interventions.